Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
485 hedge funds and large institutions have $24.8B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2023 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 156 increasing their positions, 209 reducing their positions, and 71 closing their positions.
14% more capital invested
Capital invested by funds: $21.8B → $24.8B (+$3.07B)
11% more funds holding in top 10
Funds holding in top 10: 72 → 80 (+8)
7% less funds holding
Funds holding: 519 → 485 (-34)
25% less repeat investments, than reductions
Existing positions increased: 156 | Existing positions reduced: 209
45% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 71
62% less call options, than puts
Call options by funds: $1.62B | Put options by funds: $4.26B
Top Buyers
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$358M |
| 2 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$304M |
| 3 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$219M |
| 4 |
HI
HBK Investments
Dallas,
Texas
|
+$207M |
| 5 |
PC
Paulson & Co
New York
|
+$172M |
Top Sellers
HZNP Hedge Fund Activity: Q3 2023 in Review
485 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q3 2023, worth a combined $24.8B — up 14% from $21.8B a quarter earlier.
Sellers outnumbered buyers: 71 funds closed out of HZNP and 39 opened new positions — a net loss of 32 holders — while 209 trimmed existing stakes and 156 added.
The largest buyer was UBS O'Connor, adding an estimated $358M. The largest seller was Deutsche Bank, cutting an estimated $167M.
- 485 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q3 2023, down from 519 in Q2 2023.
- Funds reported $24.8B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q3 2023, up 14% quarter-over-quarter.
- 39 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q3 2023 and 71 closed out, a net change of -32 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q3 2023 was UBS O'Connor, an estimated $358M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q3 2023 was Deutsche Bank, an estimated $167M sold.
Based on aggregated 13F filings for Q3 2023.